ALERT:

Clinical Trial

Cancer Clinical Trial 20193080

[LCID Study Number: 20193080]

Cemiplimab Survivorship Epidemiology (CASE) Study

This is a prospective study designed to collect long-term data regarding the characteristics and survivorship of patients with advanced and metastatic cutaneous squamous cell carcinoma (aCSCC) who receive cemiplimab, and to characterize real-world use patterns and effectiveness of cemiplimab for aCSCC. This is the first survivorship and epidemiology study for patients with aCSCC, and represents an important opportunity to shed light on a cancer type that previously has not been well described in the literature.

Disease/Condition: Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: cancerclinicaltrials@lahey.org

Primary Contact Phone: 781-744-3421

Clinical Trial Details

View NCT ID 03836105 on ClinicalTrials.gov

Protocol #: 20193080

Principal Investigator(s): Karl J. D'Silva

Trial Phase: Sponsor Initiated Study Observational